RecruitingPhase 3NCT06446310

Phase 3 Study of QLG2198 in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus

Studying Uremic pruritus

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Qilu Pharmaceutical (Hainan) Co., Ltd.
Principal Investigator: Zuo Li
Peking University People's Hospital
Intervention: QLG2198(drug)
Enrollment: 194 target
Eligibility: 18-85 years · All sexes
Timeline: 2024 – 2025

Study locations (3)

Peking University People's Hospital, Beijing, Beijing Municipality, China
Jieyang People's Hospital, Jieyang, Guangdong, China
Shandong Provincial Hospital, Jinan, Shandong, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06446310 on ClinicalTrials.gov

← Back to all trials